AI assistant
NYRADA INC. — Major Shareholding Notification 2021
Jun 29, 2021
65469_rns_2021-06-29_741553ae-128f-4e51-b5ba-9b7fb5c43dac.pdf
Major Shareholding Notification
Open in viewerOpens in your device viewer
Sydney, Australia
==> picture [596 x 114] intentionally omitted <==
30 June 2021
Notice of Change of Interests of Substantial Securityholder
Sydney, 30 June 2021: Nyrada Inc (ASX: NYR), advises, further to the Deed Poll dated 6 January 2020 issued by the Company in favour of ASX Limited in respect of the Initial Public Offering of its Chess Depositary Interests (“CDIs”), a Change of Interests of a Substantial Holder in relation to Nyrada. Details of the change in CDIs (“Relevant Interests”) are as follows:
Name of Substantial Holder of Relevant Interests: Altnia Holdings Pty Ltd <I Dixon FT A/C> & Helium Management Pty Ltd <Helium S/F A/C>
Date of change in the interests of the Substantial Holder : 29 June 2021
Previous and present voting power of Substantial Holder (through CHESS Depository Nominees Pty Ltd):
| Nominees Pty Ltd): | Nominees Pty Ltd): | ||
|---|---|---|---|
| Previous notice | Present notice | ||
| Number of CDIs | Voting power | Number of CDIs | Voting Power |
| 9,921,725 | 7.16% | 10,114,033 | 6.48% |
Present Relevant Interests:
| Present Relevant Interests: | |||
|---|---|---|---|
| Holder of Relevant Interest | Registered Holdings of CDIs | RelevantInterestNumber of CDIs | VotingPower |
| Altnia Holdings Pty Ltd<I Dixon FT A/C> | Altnia Holdings Pty Ltd<I Dixon FT A/C> | 9,921,725 | 6.36% |
| Helium Management Pty Ltd<Helium S/F A/C> | Helium Management Pty Ltd<Helium S/F A/C> | 192,308 | 0.12% |
- ENDS -
Nyrada Inc. Level 3, 828 Pacific Highway GORDON, NSW 2072
Nyrada Inc. ARBN 625 401 818
==> picture [596 x 114] intentionally omitted <==
About Nyrada Inc
Nyrada is a preclinical stage, drug discovery and development company, specialising in novel small molecule drugs to treat cardiovascular and neurological diseases. The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, US, and the liability of its stockholders is limited.
www.nyrada.com
Authorised by John Moore, Non-Executive Chairman, on behalf of the Board.
Investor & Corporate Enquiries:
Investor & Corporate Enquiries: Company Secretary: Laura Vize David Franks Investor Relations Manager T: 02 8072 1400 T: 0417 026 056 E: [email protected] E: [email protected]
Media Enquiries:
Catherine Strong Citadel-MAGNUS T: 02 8234 0111 E: [email protected]
Nyrada Inc. Level 3, 828 Pacific Highway GORDON, NSW 2072
Nyrada Inc. ARBN 625 401 818